This new volume of Methods in Enzymology continues the legacy of this premier serial with quality chapters authored by leaders in the field. This volume covers research methods providing a a theoretical overview on metabolic alterations of cancer cells and a series of protocols that can be employed to study oncometabolism, in vitro, ex vivo and in vivo. Malignant cells exhibit metabolic changes when compared to their normal counterparts, owing to both genetic and epigenetic alterations. Although such a metabolic rewiring has recently been indicated as "yet another" general hallmark of cancer, accumulating evidence suggests that the metabolic alterations of each neoplasm rather represent a molecular signature that intimately accompanies, and hence cannot be severed from, all facets of malignant transformation.
This new volume of Methods in Enzymology continues the legacy of this premier serial with quality chapters authored by leaders in the field. This volume covers research methods providing a a theoretical overview on metabolic alterations of cancer cells and a series of protocols that can be employed to study oncometabolism, in vitro, ex vivo and in vivo. Malignant cells exhibit metabolic changes when compared to their normal counterparts, owing to both genetic and epigenetic alterations. Although such a metabolic rewiring has recently been indicated as "yet another" general hallmark of cancer, accumulating evidence suggests that the metabolic alterations of each neoplasm rather represent a molecular signature that intimately accompanies, and hence cannot be severed from, all facets of malignant transformation.
This new volume of Methods in Enzymology continues the legacy of this premier serial with quality chapters authored by leaders in the field.
1. Methods to measure cytoplasmic and mitochondrial Ca2+ concentration using Ca2+-sensitive dyes2. Methods to measure intracellular Ca2+ fluxes with Organelle-Targeted aequorin-based probes3. Methods to measure baseline Ca2+ levels with second-generation organelle-targeted fluorescent probes4. Methods to assess the autophagic flux in malignant cells5. Methods to assess autophagy in situ-transmission electron microscopy versus immunohistochemistry6. Methods to measure the enzymatic activity of PI3Ks7. Luciferase-based reporter to monitor the transcriptional activity of the SIRT3 promoter8. Metabolomic profiling of cultured cancer cells9. Pulsed stable isotope-resolved metabolomic studies of cancer cells10. Single-cell imaging for the study of oncometabolism 11. Study of cellular oncometabolism via multi-dimensional protein identification technology12. In vivo quantitative proteomics for the study of oncometabolism13. Metabolomic profiling of neoplastic lesions in mice14. Metabolomic profiling of tumor-bearing mice15. Metabolomic studies of patient material by high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy16. Analysis of metabolomic profiling data acquired on GC–MS
Lorenzo Galluzzi is Assistant Professor of Cell Biology in
Radiation Oncology at the Department of Radiation Oncology of the
Weill Cornell Medical College, Honorary Assistant Professor Adjunct
with the Department of Dermatology of the Yale School of Medicine,
Honorary Associate Professor with the Faculty of Medicine of the
University of Paris, and Faculty Member with the Graduate School of
Biomedical Sciences and Biotechnology of the University of Ferrara,
the Graduate School of Pharmacological Sciences of the University
of Padova, and the Graduate School of Network Oncology and
Precision Medicine of the University of Rome “La Sapienza.
Moreover, he is Associate Director of the European Academy for
Tumor Immunology and Founding Member of the European Research
Institute for Integrated Cellular Pathology.
Galluzzi is best known for major experimental and conceptual
contributions to the fields of cell death, autophagy, tumor
metabolism and tumor immunology. He has published over 450 articles
in international peer-reviewed journals and is the Editor-in-Chief
of four journals:
OncoImmunology (which he co-founded in 2011), International Review
of Cell and Molecular Biology, Methods in Cell biology, and
Molecular and Cellular Oncology (which he co-founded in 2013).
Additionally, he serves as Founding Editor for Microbial Cell and
Cell Stress, and Associate Editor for Cell Death and Disease,
Pharmacological Research and iScience. Guido Kroemer got his M.D.
in 1985 from the University of Innsbruck, Austria, and his Ph.D. in
molecular biology in 1992 from the Autonomous University of Madrid,
Spain. He is currently Professor at the Faculty of Medicine of the
University of Paris Descartes/Paris V, Director of the INSERM
research team ‘Apoptosis, Cancer and Immunity’, Director of the
Metabolomics and Cell Biology platforms of the Gustave Roussy
Cancer Campus, and Practitioner at the Hôpital Européen George
Pompidou (Paris, France). He is also the Director of the Paris
Alliance of Cancer Research Institutes (PACRI) and the Labex
'Immuno-Oncology'. Dr. Kroemer is best known for the discoveries
that mitochondrial membrane permeabilization constitutes a decisive
step in regulated cell death; that autophagy is a cytoprotective
mechanism with lifespan-extending effects; and that anticancer
therapies are successful only if they stimulate tumour-targeting
immune responses. He is currently the most-cited cell biologist in
Europe (relative to the period 2007-2013), and he has received the
Descartes Prize of the European Union, the Carus Medal of the
Leopoldina, the Dautrebande Prize of the Belgian Royal Academy of
Medicine, the Léopold Griffuel Prize of the French Association for
Cancer Research, the Mitjavile prize of the French National Academy
of Medicine and a European Research Council Advanced Investigator
Award.
|
Ask a Question About this Product More... |
|
